June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
ROCK inhibitor Ripasudil (K-115) suppresses subretinal fibrosis in laser-induced CNV model
Author Affiliations & Notes
  • Iori Wada
    Kyu-shu university, Fukuoka, Japan
  • Shintaro Nakao
    Kyu-shu university, Fukuoka, Japan
  • Muneo Yamaguchi
    Kyu-shu university, Fukuoka, Japan
  • Keijiro Ishikawa
    Kyu-shu university, Fukuoka, Japan
  • Shigeo Yoshida
    Kyu-shu university, Fukuoka, Japan
  • Yoshihiro Kaizu
    Kyu-shu university, Fukuoka, Japan
  • Tomoyuki Isobe
    Tokyo New Drug Research Laboratories, Kowa Company, Tokyo, Japan
  • Yoshio Kaneko
    Tokyo New Drug Research Laboratories, Kowa Company, Tokyo, Japan
  • Tatsuro Ishibashi
    Kyu-shu university, Fukuoka, Japan
  • Koh-hei Sonoda
    Kyu-shu university, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Iori Wada, None; Shintaro Nakao, Tokyo New Drug Research Laboratories, Kowa Company (P); Muneo Yamaguchi, None; Keijiro Ishikawa, None; Shigeo Yoshida, None; Yoshihiro Kaizu, None; Tomoyuki Isobe, Tokyo New Drug Research Laboratories, Kowa Company (E); Yoshio Kaneko, Tokyo New Drug Research Laboratories, Kowa Company (E); Tatsuro Ishibashi, Tokyo New Drug Research Laboratories, Kowa Company (P); Koh-hei Sonoda, None
  • Footnotes
    Support  JSPS KAKENHI (Tokyo, Japan), Grant-in-Aid for Young Scientists No. 25713057 and grants from Kowa Company, Ltd. (Tokyo, Japan).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Iori Wada, Shintaro Nakao, Muneo Yamaguchi, Keijiro Ishikawa, Shigeo Yoshida, Yoshihiro Kaizu, Tomoyuki Isobe, Yoshio Kaneko, Tatsuro Ishibashi, Koh-hei Sonoda; ROCK inhibitor Ripasudil (K-115) suppresses subretinal fibrosis in laser-induced CNV model. Invest. Ophthalmol. Vis. Sci. 2017;58(8):259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis is known to develop occasionally in neovascular age-related macular degeneration after anti-VEGF therapy. However, there is no appropriate treatment for the fibrosis. The purpose of this study was to investigate the impact of a Rho-associated coiled coil–containing protein kinase (ROCK) inhibitor ripasudil (K-115) on the subretinal fibrosis after choroidal neovascularization.

Methods : C57BL/6J mice underwent laser photocoagulation to induce CNV-related fibrosis. Ripasudil (3 or 30 μmol/L) and fasudil (30 μmol/L) were treated intravitreally every 3 days from the 14th day after laser injury. The volume of fibrosis was quantified with flat mounts stained by type 1 collagen on day 28 after laser injury.

Results : Intravitreal high but not low concentration ripasudil treatment could reduce the volumes of fibrosis significantly (46.6% reduction from baseline at 30 μmol/L ripasudil; p<0.05 vs control and 5.0% reduction from baseline at 3 μmol/L ripasudil; p=0.99 vs control). On the other hand, fasudil could not affect significantly the volumes of fibrosis (26.4% reduction from baseline at 30 μmol/L fasudil; p=0.50 vs control).

Conclusions : Novel ROCK inhibitior ripasudil has the therapeutic potential for the treatment of subretinal fibrosis in neovascular age-related macular degeneration.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×